Patents Examined by Kay Kim
  • Patent number: 5037805
    Abstract: Methods are disclosed for regulating ovulation or fertility in female mammals, for regulating spermatogenesis in males and for treating conditions such as endometriosis. Administration of effective amounts of an FSH-Inhibiting Protein (FSH-IP) can be used for female contraception and also for male contraception by preventing sperm production. FSH-IP, in its native form, is a glycosylated protein having an apparent molecular weight of about 50,000 Daltons (50kD) which inhibits the production of estradiol that would otherwise be stimulated by FSH in certain cells, such as granulosa cells. Antibodies to these FSH-IP proteins, preferably of monoclonal form can be produced using techniques presently known in the art and are useful for treatment to promote ovulation or superovulation in mammals, including humans and livestock.
    Type: Grant
    Filed: March 20, 1989
    Date of Patent: August 6, 1991
    Assignee: The Salk Institute for Biological Studies
    Inventor: Nicholas C. Ling
  • Patent number: 5034514
    Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--XwhereinL is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from: --CO--Y--CONHNH.sub.2, a hydrazide; ##STR1## a hydrazine; ##STR2## a hydrazine; --CO--Y--NH--CONHNH.sub.2, a semicarbazide; and --CO--Z--NH--CSNHNH.sub.2, a thiosemicarbazide;wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue briding the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected froma) --(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 -- wherein each n2 is independently 2-4 andb) ##STR3## wherein n3 is 2-6.
    Type: Grant
    Filed: October 12, 1988
    Date of Patent: July 23, 1991
    Assignee: Cetus Corporation
    Inventors: Danute E. Nitecki, Margaret Moreland
  • Patent number: 5032518
    Abstract: The present invention provides a hapten-protein conjugate, wherein a hapten is bound to the reducing end of a sugar which consists of up to 10 monosaccharide units and on a free CH.sub.2 OH group on the other end of the sugar, which is in the .alpha.-position to a hydroxyl group, is bound a protein.
    Type: Grant
    Filed: January 25, 1989
    Date of Patent: July 16, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Erasmus Huber, Hans-Georg Batz, Herbert von der Eltz, Christian Klein
  • Patent number: 5030719
    Abstract: Cytotoxic antibody conjugates in which a folic acid-antagonistic folic acid analogue is bound to an antibody or its fragment through an oligopeptide. The conjugates can be used as a chemotherapeutic agent against malignant tumors.
    Type: Grant
    Filed: April 27, 1988
    Date of Patent: July 9, 1991
    Assignee: Teijin Limited
    Inventors: Naoji Umemoto, Yoshinori Kato, Takeshi Hara
  • Patent number: 5028692
    Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
    Type: Grant
    Filed: April 25, 1989
    Date of Patent: July 2, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Allen I. Oliff, Walfred S. Saari
  • Patent number: 5028697
    Abstract: Conjugates of antibodies and cytotoxic methotrexate drugs make use of linkers between the drug and antibody which are simple organic groups, wherein the link to the antibody is an acyl group and the link to the drug is an alkylidene hydrazide.
    Type: Grant
    Filed: August 8, 1988
    Date of Patent: July 2, 1991
    Assignee: Eli Lilly and Company
    Inventors: David A. Johnson, Bennett C. Laguzza, William L. Scott
  • Patent number: 5026827
    Abstract: A N-(4-aminobutyl)amphetamine-protein complex has been synthesized to be used as an immunogen to prepare an antibody having a high affinity to methamphetamine. The antibody prepared by the use of the complex has 1,000 times the affinity to methamphetamine as that of an antibody prepared by the use of N-(4-aminobutyl)methamphetamine-protein complex as an immunogen.
    Type: Grant
    Filed: August 31, 1989
    Date of Patent: June 25, 1991
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Jinsei Miyazaki, Makoto Taketani, Tadayasu Mitsumata
  • Patent number: 5024834
    Abstract: Heterobifunctional crosslinkers up to about 34 .ANG. in length consisting of a sulfhydryl reactive group linked to a spacer group, which in turn is linked to an activated carboxylate group, that are useful for making efficacious anticancer immunotoxin conjugates as shown preferably by reacting an antibody associated amino group with the activated carboxylate group to form an antibody crosslinker complex and reacting the antibody crosslinker complex with a cytotoxin having a reactive sulfhydryl group with the sulfhydryl reactive group of the crosslinker, and using the conjugates so produced to treat cancer patients.
    Type: Grant
    Filed: October 15, 1990
    Date of Patent: June 18, 1991
    Assignee: Cetus Corporation
    Inventors: L. L. Houston, Lois Aldwin, Danute E. Nitecki
  • Patent number: 5024835
    Abstract: The subject of the present invention is conjugates of vinca (indole-dihydroindole) derivatives carrying a detergent chain of at least 7 aliphatic carbon atoms in the C-3 position bonded via a covalent bond to a macromolecular carrier of polypeptide character, and also pharmaceutical compositions containing these conjugates and a process of preparation.
    Type: Grant
    Filed: February 3, 1989
    Date of Patent: June 18, 1991
    Assignee: Ire-Celltarg S.A.
    Inventors: KSP Siva Bhushana Rao, Jean-Paul Dejonghe, Marie-Paule Collard, Andre Trouet
  • Patent number: 5019647
    Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
    Type: Grant
    Filed: May 24, 1988
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Allen I. Oliff, Walfred S. Saari, David C. Heimbrook
  • Patent number: 5013547
    Abstract: A drug-protein conjugate of the general formula (I): ##STR1## where the moiety A--NH-- is the condensation product of an anticancer antibiotic having a free amino group, n is 0, 1 or 2, m is 0, 1, 2 or 3, the moiety --NHAB is the condensation product of a protein having a free amino group and the moiety ##STR2## is the condensation product of an amino acid of the formula HOOC--AA--NH.sub.2.
    Type: Grant
    Filed: February 7, 1989
    Date of Patent: May 7, 1991
    Assignee: Erbamont, Inc.
    Inventors: Frederick Sweet, Leonard O. Rosik
  • Patent number: 5011913
    Abstract: Diphosphonate-derivatized macromolecules, such as proteins, suitable for use as technetium-99m-based scanning agents and as anticalcification agents are disclosed. The scanning agents are prepared by combining Tc-99m in a +3, +4 and/or +5 oxidation state with the diphosphonate-derivatized macromoleules. Also disclosed are pharmaceutical compositions containing these diphosphonate-derivatized macromolecules and methods for scintigraphic imaging using these diphosphonate-derivatized macromolecules labeled with Tc-99m.
    Type: Grant
    Filed: May 11, 1989
    Date of Patent: April 30, 1991
    Assignee: The Procter & Gamble Company
    Inventors: James J. Benedict, Charles R. Degenhardt, James W. Poser
  • Patent number: 5010176
    Abstract: Modified antibodies or antigen-recognizing fragments are prepared with a linker consisting of a malonate, wherein the antibody or fragment thereof is attached through a carbonyl to an ester or amide group on one of the malonate carboxyls, and the drug is linked through a methylene to the 2-position carbon of the malonate.
    Type: Grant
    Filed: November 10, 1988
    Date of Patent: April 23, 1991
    Assignee: Eli Lilly and Company
    Inventor: Russell L. Barton
  • Patent number: 5002883
    Abstract: Novel methods for covalent attachment of antibodies, antigens, or other molecules to solid phases using extended length heterobifunctional crosslinking reagents are disclosed. The resulting derivatized solid phases can be used in diagnostic assays.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: March 26, 1991
    Assignee: Abbott Laboratories
    Inventors: Christopher Bieniarz, Christopher J. Welch, Grady Barnes, Carol A. Schlesinger
  • Patent number: 4994385
    Abstract: Novel polyamino acid based coupling agents are disclosed. These reagents are useful for conjugating proteins (e.g. antibodies to enzymes) for use in diagnostic assays.
    Type: Grant
    Filed: September 22, 1988
    Date of Patent: February 19, 1991
    Assignee: Abbott Laboratories
    Inventors: Christopher Bieniarz, Christopher J. Welch, Grady Barnes